$173.91Peak — highest point inside the window, not a realized return
$172.06Window close — end-of-window price, context only
What happened
Partial
Reached 9% of the predicted growth at its peak, without hitting the target.
At window close
-0%
realized, from the publication price to the last close inside the window
Peak gain
+1.1%
peak, from the publication price — not a realized return
S&P 500, same window
+3.6%
SPY over the identical days, dividend-adjusted
Window close
$172.06
last close inside the window, ended October 26, 2026
Peak price
$173.91
peak on October 22, 2026 — not a realized return
Days to target
—
The thesis — published July 28, 2026
Predicted growth
+12%
over the measurement window
Target price
$191.46
the price the thesis aimed for
Entry zone
$165.80 – $171.72
the fair-value band we waited for
Price at publication
$172.08
published July 28, 2026
Confidence
68%
how strongly the data lined up
Timeframe
Short-term (0–3 months)
AstraZeneca sells many different prescription drugs across cancer and other specialty areas, which spreads risk. Recent profit and cash strength were weaker than the headline growth story. The stock is near its short-term trend and momentum is negative. Opinions on drug trials are split, so the next few months depend on clearer clinical news.
Primary drivers
Broad cancer and specialty drug lineup
Important upcoming trial and sales updates
Stock less sensitive to market swings
Opinions split after recent trial setbacks
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.